title: [Treatment of painful diabetic polyneuropathy].
abstract: Painful neuropathy is a common complication of diabetes and causes disability and impaired quality of life. Treatment of neuropathy aims at pain relief, improved function and quality of life and avoidance of foot ulcers. Progression of neuropathy is prevented with good glycemic control and treatment of the risk factors of atherosclerosis. In pain relief the first-line drugs are tricyclic antidepressants, SNRIs and gabapentinoids. Comorbidities, concomitant medications and possible contraindications are taken into account in drug selection. Since treatment with a single agent does not provide sufficient pain relief, combination of two drugs with different mechanism of action is recommended. Most patients need long-term treatment.
authors.forename: Maija
authors.initials: M
authors.lastname: Haanpää
mesh_terms: D000588:Amines / Q000627:therapeutic use; D000700:Analgesics / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D017719:Diabetic Foot / Q000517:prevention & control*; D003929:Diabetic Neuropathies / Q000188:drug therapy* / Q000503:physiopathology; D018450:Disease Progression; D004359:Drug Therapy, Combination; D006801:Humans; D059408:Pain Management / Q000379:methods*; D011788:Quality of Life; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives
chemical_list: D000588:Amines; D000700:Analgesics; D000929:Antidepressive Agents, Tricyclic; D003509:Cyclohexanecarboxylic Acids; D017367:Selective Serotonin Reuptake Inhibitors; D005680:gamma-Aminobutyric Acid